El CRAI romandrà tancat del 24 de desembre de 2025 al 6 de gener de 2026. La validació de documents es reprendrà a partir del 7 de gener de 2026.
El CRAI permanecerá cerrado del 24 de diciembre de 2025 al 6 de enero de 2026. La validación de documentos se reanudará a partir del 7 de enero de 2026.
From 2025-12-24 to 2026-01-06, the CRAI remain closed and the documents will be validated from 2026-01-07.
 
Miniatura

Fitxers

260923.pdf (230.84 KB)

Tipus de document

Article

Versió

Versió publicada

Data de publicació

2023-06

Llicència de publicació

cc-by-nc-nd (c) Springer, J. et al., 2023
Si us plau utilitzeu sempre aquest identificador per citar o enllaçar aquest document: https://hdl.handle.net/2445/219227

Effects of S-pindolol in mouse pancreatic and lung cancer cachexia models

Títol de la revista

Autors

Director/Tutor

ISSN de la revista

Títol del volum

Recurs relacionat

https://doi.org/10.1002/jcsm.13249

Resum

Background: It is known that S-pindolol attenuates muscle loss in animal models of cancer cachexia and sarcopenia. In cancer cachexia, it also significantly reduced mortality and improved cardiac function, which is strongly compromised in cachectic animals. Methods: Here, we tested 3 mg/kg/day of S-pindolol in two murine cancer cachexia models: pancreatic cancer cachexia (KPC) and Lewis lung carcinoma (LLC). Results: Treatment of mice with 3 mg/kg/day of S-pindolol in KPC or LLC cancer cachexia models significantly attenuated the loss of body weight, including lean mass and muscle weights, leading to improved grip strength compared with placebo-treated mice. In the KPC model, treated mice lost less than half of the total weight lost by placebo (−0.9 ± 1.0 vs. −2.2 ± 1.4 g for S-pindolol and placebo, respectively, P < 0.05) and around a third of the lean mass lost by tumour-bearing controls (−0.4 ± 1.0 vs. −1.5 ± 1.5 g for S-pindolol and placebo, respectively, P < 0.05), whereas loss of fat mass was similar. In the LLC model, the gastrocnemius weight was higher in sham (108 ± 16 mg) and S-pindolol tumour-bearing (94 ± 15 mg) mice than that in placebo (83 ± 12 mg), whereas the soleus weight was only significantly higher in the S-pindolol-treated group (7.9 ± 1.7 mg) than that in placebo (6.5 ± 0.9). Grip strength was significantly improved by S-pindolol treatment (110.8 ± 16.2 vs. 93.9 ± 17.1 g for S-pindolol and placebo, respectively). A higher grip strength was observed in all groups; whereas S-pindolol-treated mice improved by 32.7 ± 18.5 g, tumour-bearing mice only show minimal improvements (7.3 ± 19.4 g, P < 0.01). Conclusions: S-pindolol is an important candidate for clinical development in the treatment of cancer cachexia that strongly attenuates loss of body weight and lean body mass. This was also seen in the weight of individual muscles and resulted in higher grip strength.

Matèries

Càncer de pulmó, Pes corporal, Càncer, Caquèxia

Matèries (anglès)

Lung cancer, Body weight, Cancer, Cachexia

Citació

Col·leccions

Articles publicats en revistes (Bioquímica i Biomedicina Molecular)
Articles publicats en revistes (Institut de Biomedicina (IBUB))

Citació

SPRINGER, Jochen, JOVÉ, Queralt, ALVES DE LIMA JUNIOR, Edson, ÁLVAREZ LADRÓN, Natalia, LÓPEZ-SORIANO, Francisco j., BUSQUETS RIUS, Sílvia, ARGILÉS HUGUET, Josep ma., MARKS, Daniel l.. Effects of S-pindolol in mouse pancreatic and lung cancer cachexia models. _Journal of Cachexia Sarcopenia and Muscle_. 2023. Vol. 14, núm. 3, pàgs. 1244-1248. [consulta: 25 de desembre de 2025]. ISSN: 2190-5991. [Disponible a: https://hdl.handle.net/2445/219227]

Exportar metadades

JSON - METS

Compartir registre